Given that ccRCC is characterized as a “metabolism-related disease,” particularly in terms of lipid metabolism, the unexplored HIF-2α/LPCAT1/ACLY pathway may present a promising therapeutic target for controlling this tumor. This evidence concerns the gene EPAS1 and neoplasm.